- Stocks
- Pharma & Healthcare
- Wockhardt
Wockhardt share price
NSE: WOCKPHARMAPharma & HealthcareDrug Manufacturers - Specialty & Generic
Wockhardt at a glance
Wockhardt (NSE: WOCKPHARMA) closed at ₹1,905.90 on 21 Oct 2026. With a market capitalisation of ₹32,678 Cr, it ranks 240th by market cap among the 3,928 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 4.3% in FY26. Its 52-week range is ₹1,086.70 (23 Mar 2026) to ₹2,422.30 (1 Jun 2026); the last close is 21.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹965 Cr (+29.9% year on year) and net profit ₹164 Cr, on a consolidated basis. Promoters held 49.08% of the company as of 30 Jun 2026; 14.68% of promoter shares were pledged.
Key numbers
- Market cap
- ₹32,678 CrRank 240 on NSE
- Price to book
- 3.86×FY26
- EPS (TTM)
- ₹13.32to Q4 FY26
- ROE
- 4.3%FY26
- ROCE
- 7.7%FY26
- Debt to equity
- 0.43FY26
- Net profit margin
- 5.9%FY26
- Book value / share
- ₹304.94FY26
- 52-week high
- ₹2,422.301 Jun 2026
- 52-week low
- ₹1,086.7023 Mar 2026
Returns to —
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Wockhardt quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹739 Cr | ₹809 Cr | ₹721 Cr | ₹743 Cr | ₹738 Cr | ₹782 Cr | ₹888 Cr | ₹965 Cr |
| Revenue YoY | +14.8% | +7.4% | +2.9% | +6.1% | −0.1% | −3.3% | +23.2% | +29.9% |
| Net profit | −₹16 Cr | −₹16 Cr | ₹20 Cr | −₹45 Cr | −₹108 Cr | ₹82 Cr | ₹61 Cr | ₹164 Cr |
| Net profit YoY | — | — | — | — | — | — | +205.0% | — |
| Net margin | −2.2% | −2.0% | 2.8% | −6.1% | −14.6% | 10.5% | 6.9% | 17.0% |
| EPS | −₹0.95 | −₹1.47 | ₹0.91 | −₹1.57 | −₹5.33 | ₹4.81 | ₹3.61 | ₹10.23 |
Wockhardt financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹2,708 Cr | ₹3,230 Cr | ₹2,651 Cr | ₹2,798 Cr | ₹3,012 Cr | — |
| Operating profit | −₹426 Cr | −₹228 Cr | −₹330 Cr | −₹406 Cr | −₹16 Cr | — |
| Net profit | ₹689 Cr | −₹279 Cr | −₹621 Cr | −₹472 Cr | −₹57 Cr | — |
| EPS (₹) | ₹62.00 | −₹20.00 | −₹39.00 | −₹32.00 | −₹3.00 | — |
| Cash from operations | −₹287 Cr | ₹413 Cr | ₹153 Cr | ₹219 Cr | −₹22 Cr | — |
| Total debt | ₹503 Cr | ₹355 Cr | ₹224 Cr | ₹891 Cr | ₹1,211 Cr | ₹1,518 Cr |
| Shareholders' equity | ₹3,377 Cr | ₹3,849 Cr | ₹3,354 Cr | ₹3,359 Cr | ₹4,353 Cr | ₹4,940 Cr |
Wockhardt shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 49.09% | 49.09% | 49.08% | 49.08% | 49.08% | 49.08% |
| Foreign institutions | 6.81% | 7.29% | 7.10% | 6.99% | 7.09% | 7.22% |
| Domestic institutions | 10.59% | 11.01% | 11.01% | 10.55% | 10.96% | 9.24% |
| Non-institutions | 33.50% | 32.60% | 32.79% | 33.35% | 32.83% | 34.44% |
| Promoter shares pledged | 18.24% | 15.64% | 21.30% | 18.04% | 18.82% | 14.68% |
Wockhardt vs peers
The listed Pharma & Healthcare companies nearest to Wockhardt by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| AJANTPHARMAjanta Pharma | — | — | — | ₹38,295 Cr | — | — |
| NHNarayana Hrudayalaya | — | — | — | ₹38,156 Cr | — | — |
| GLANDGland Pharma | — | — | — | ₹36,274 Cr | — | — |
| MEDANTAGlobal Health | — | — | — | ₹34,013 Cr | — | — |
| WOCKPHARMAWockhardt | — | — | — | ₹32,678 Cr | — | — |
| KIMSKrishna Institute of Medical Sciences | — | — | — | ₹32,181 Cr | — | — |
| PGHHProcter Gamble | — | — | — | ₹30,105 Cr | — | — |
Ask anything about Wockhardt
Pivot answers on the live chart with evidence you can check, and tests strategies against WOCKPHARMA's own history. Try: “Why has WOCKPHARMA moved over the last three months?” · “Backtest a 50-day moving-average crossover on WOCKPHARMA over five years” · “Compare WOCKPHARMA with AJANTPHARM on margins and valuation”
Frequently asked questions about Wockhardt
What is the share price of Wockhardt today?
Wockhardt (NSE: WOCKPHARMA) last closed at ₹1,905.90 on 21 Oct 2026. Its 52-week high is ₹2,422.30 and its 52-week low is ₹1,086.70.
What is the market cap of Wockhardt?
Wockhardt's market capitalisation is ₹32,678 Cr (₹32,678 Cr) at the — close, ranking 240th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Wockhardt?
Return on equity was 4.3% in FY26 and return on capital employed was 7.7% in FY26 (consolidated figures).
Is Wockhardt a debt-free company?
No. Wockhardt's debt-to-equity ratio was 0.43 in FY26, with total debt of ₹1,518 Cr.
What were Wockhardt's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Wockhardt reported revenue of ₹965 Cr, +29.9% year on year, and net profit of ₹164 Cr.
What is the shareholding pattern of Wockhardt?
As of 30 Jun 2026: promoters 49.08%, foreign institutions 7.22%, domestic institutions 9.24%, non-institutions 34.44%. 14.68% of promoter shares were pledged.
Who are Wockhardt's competitors?
The listed Pharma & Healthcare companies closest to Wockhardt by market cap are Ajanta Pharma, Narayana Hrudayalaya, Gland Pharma, Global Health, Krishna Institute of Medical Sciences and Procter Gamble.
Is Wockhardt a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Wockhardt's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on WOCKPHARMA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026. Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 3,928 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with W · all NSE stocks · this page as text